Universal Health Services (UHS) Stock Looks Cheap On Earnings While Returns Look Strong

Universal Health Services stock has retreated this year after a solid three year run, yet the broader valuation checks still lean cheap relative to that recent performance. The question for investors is whether the current share price around US$169.65 still reflects enough caution in relation to the company’s fundamentals.

• Over the past 3 years the stock has returned 30.7%, which suggests the market has already reassessed Universal Health Services more positively over that period.
• Future valuation can hinge on how consistently the company converts revenue into cash flow. Any pressure on margins or higher capital spending needs may weigh on what investors are willing to pay.
• The broader checks lean cheap, with Universal Health Services screening as undervalued on most measures and carrying a value score of 5 out of 6.

The issue now is whether that high value score and the recent share price pullback together leave enough potential upside to justify fresh capital at today’s level.

Compare Universal Health Services' recent pullback and high value score with other potentially mispriced stocks by scanning our hand-picked list of 47 high quality undervalued stocks.

Is Universal Health Services a Bargain on Earnings?

The P/E ratio is a useful starting point for Universal Health Services because earnings are a key marker for hospital operators. On this basis, Universal Health Services trades on a P/E of about 6.6x, compared with a Healthcare industry average of roughly 25.0x and a peer group average near 20.1x.

The fair P/E ratio implied by the broader checks is about 20.9x, which is significantly higher than the current 6.6x multiple. That gap suggests the market is pricing Universal Health Services at a steep discount to what might be expected given its profile, while peers and the wider Healthcare sector trade on much richer earnings multiples.

On the P/E multiple alone, Universal Health Services stock appears undervalued relative to both its fair ratio and typical sector levels.

See what the numbers say about this price — find out in our valuation breakdown.

The Universal Health Services Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Universal Health Services pick up where the valuation puzzle leaves off. They spell out which paths for growth, margins and earnings would need to play out for the stock to be worth materially more or less than today’s price. Each narrative ties its number to a clear view on how Universal Health Services' growth, profitability and risks might evolve, which you can return to as new information comes through on the Community page.

Community views on Universal Health Services are sharply split, with some focusing on the behavioral health opportunity and others on reimbursement and cost pressure risks.

Bull case: 24% undervalued

“Organizations that can offer structured, evidence-based treatment at scale are becoming increasingly vital to the healthcare ecosystem…”

Read the full Bull Case to see why Universal Health Services could be undervalued

Bear case: roughly fairly valued

“Beginning in 2028, recent Medicaid legislation will sharply reduce Universal Health Services' supplemental payment benefits by approximately $360 million to $400 million annually by 2032…”

Read the full Bear Case to see why Universal Health Services could be overvalued

Do you think there's more to the story for Universal Health Services? Head over to our Community to see what others are saying!

The Bottom Line

Universal Health Services still screens as undervalued on earnings multiples, which points to a discount against much of the Healthcare sector. The broader valuation checks also lean supportive rather than signalling a clear red flag. For you, the key question is whether margins and cash generation stay resilient enough for that earnings gap with peers to close. The crux of the bull versus bear debate is whether the current discount reflects mispricing around the behavioural health and hospital opportunity, or a justified response to reimbursement and policy risks that could limit any future re rating in the P/E.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com